Nuvation Bio Inc Ordinary Shares - Class A Logo
US67080N1019
A2QPAG
NUVB

Nuvation Bio Inc Ordinary Shares - Class A

Previsión

El precio objetivo medio de los analistas es de 15,47 € (+344,54 %). La mediana es de 18,20 € (+422,99 %).

Comprar
  8
Mantener
  2
Vender
  0

Debates en la comunidad

Todavía no hay ninguna discusión sobre este activo.

Iniciar debate

  • Nuvation Bio reports strong launch of IBTROZI and positive Safusidenib data

    At the Cantor Fitzgerald Healthcare Conference, Nuvation Bio said IBTROZI reached roughly 20% of the theoretical ROS1 market in its first year and uptake in first-line therapy continues to grow. The company holds $700 million in cash and considers itself well positioned financially to fund commercialization and its pipeline. Safusidenib showed a 79% non‑progression rate and a 52% response rate at 3 years, and multiple studies are planned through 2029. Management forecasts a peak sales potential for IBTROZI of $4–5 billion at full market penetration, while warning of development risks and emphasizing disciplined capital deployment. » Más en de.investing.com


  • Nuvation Bio receives FDA fast-track for safusidenib and Cantor-Fitzgerald starts coverage with 12 USD target

    The FDA granted safusidenib fast-track status for the treatment of IDH1‑mutated gliomas based on phase 2 data (confirmed objective response rate 51.9%, median progression‑free survival not yet reached, 36‑month PFS 79.1%). The designation enables more intensive interaction with the agency and a possible rolling review, reducing regulatory risk while the phase 3 SIGMA study continues to enroll. Cantor Fitzgerald initiated coverage with an “Overweight” rating and set a price target of 12 USD, with revenue forecasts of roughly 965 million USD for IBTROZI and about 1.9 billion USD for safusidenib. The news pushed the stock higher intraday (rise to 7.02 USD). » Más en de.investing.com


  • Nuvation Bio receives FDA fast-track for safusidenib in IDH1 gliomas

    The FDA has granted fast-track designation to safusidenib, an oral investigational candidate from Nuvation Bio for the treatment of IDH1‑mutant gliomas. The decision is based on phase‑2 data (J201) showing a confirmed objective response rate of 51.9% and a 36‑month progression‑free survival of 79.1%; median PFS has not yet been reached. Nuvation is currently recruiting for the registrational phase‑3 SIGMA trial, which will evaluate safusidenib as maintenance therapy versus placebo after standard treatment in IDH1‑mutant astrocytomas with high‑risk features (about 300 patients). Safusidenib is a selective inhibitor of mutant IDH1 designed to penetrate the blood–brain barrier; no new long‑term safety signals have been reported. » Más en de.investing.com


  • Nuvation Bio receives Overweight from JPMorgan after robust second quarter

    Nuvation Bio reports a solid second quarter and cash of $661 million. JPMorgan initiated coverage with an "Overweight" rating and a $13 price target, supported by expected first-line uptake. The bank sees additional revenue potential in prevalence-driven gene sequencing and in the pipeline around Safusidenib; the company remains focused on targeted cancer therapies and has a strengthened capital base. » Más en finanzen.net


  • Nuvation Bio reports Q2 revenue growth for IBTROZI and expands safusidenib trials

    Nuvation Bio posted Q2 total revenue of $31.7 million with U.S. IBTROZI product sales of $23.2 million, a 25% sequential increase as use shifts toward first-line ROS1 patients. Management highlighted stronger first-line uptake and longer treatment durations, supported by favorable TRUST-I and patient-reported outcomes. The company expanded safusidenib development with a Phase III trial in newly diagnosed Grade 2 IDH1-mutant glioma and a Phase II study for post-vorasidenib patients, citing durable Phase II results. Nuvation ended June with $661 million in cash and securities and raised about $279.1 million via convertible notes, which management says supports operations through profitability and the anticipated safusidenib launch. » Más en finance.yahoo.com

Datos financieros

En el último trimestre, Nuvation Bio Inc Ordinary Shares - Class A tuvo unos ingresos de 39,68 M € y un beneficio neto de -36,99 M €

(EUR) septiembre de 2026
YoY
Ingresos 39,68 M 254,97 %
Beneficio bruto 29,15 M 250,14 %
Beneficio neto -36,99 M 22,19 %
EBITDA -31,08 M 33,39 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
1210,55 M €
Número de acciones
352,02 M
Máximo/mínimo de 52 semanas
8,87 € - 3,43 €
Dividendos No
Beta
1,73
Ratio P/E
-9,58
Ratio PEG
-0,20
Ratio P/B
5,83
Ratio P/S
6,60

Perfil de la empresa

Nuvation Bio Inc., una empresa biofarmacéutica en fase clínica, se centra en el desarrollo de candidatos terapéuticos para la oncología. El candidato principal de la compañía es NUV-422, un inhibidor de molécula pequeña dirigido a las quinasas dependientes de ciclina (CDK)2, CDK4 y CDK6. También desarrolla NUV-868, un inhibidor BET selectivo de molécula pequeña de administración oral que regula epigenéticamente proteínas que controlan el crecimiento y la diferenciación tumoral; NUV-569, un inhibidor selectivo de molécula pequeña de administración oral y de diseño diferenciado de la quinasa Wee1 para la reparación del ADN; NUV-1182, un inhibidor del receptor de adenosina; y una plataforma de conjugados fármaco-fármaco (DDC) que se centra en dirigir un inhibidor de la poli(ADP-ribosa) polimerasa (PARP) a los warheads anticancerígenos de fármacos existentes, así como un inhibidor de PARP para abordar el cáncer de mama ER+ y el cáncer de ovario. La compañía era anteriormente conocida como RePharmation Inc. y cambió su nombre a Nuvation Bio Inc. en abril de 2019. Nuvation Bio Inc. fue fundada en 2018 y tiene su sede en Nueva York, Nueva York.

Nombre
Nuvation Bio Inc Ordinary Shares - Class A
CEO
David T. Hung
Sede New York City, ny
Estados Unidos
Sitio web
Sector
Materiales
Industria
Productos químicos
Salida a bolsa
26/08/2020
Empleados 310

Símbolos bursátiles

Bolsa Símbolo
NYSE
NUVB
🍪

Parqet  usa cookies. Más información